Hemispherx BioPharma, Inc. (NYSEMKT:HEB) Rallies 3.68%, Westinghouse Solar Inc. (OTCMKTS:WEST) Recovers to a Gain of 6.67%
Northern, WI 05/07/2013 (GDPInsider) – Hemispherx BioPharma, Inc. (NYSEMKT:HEB) is up 3.68% having started the day’s trading at 0.21. The stock had a previous close of 0.22 and is trading with a range of 0.21 and 0.23. HEB is down 80.02% on its 52-week high of 1.10 but up 22.11% on its 52-week low of 0.18. Clearly a slow-moving stock, but HEB looks to be recovering slightly from the steep decline it took late last year. The stock is up 1.95% on its 50-day simple moving average but down 1.88% on its 20-day simple moving average.
Hemispherx’s board has come under some criticism recently for the recent disbursement of sales proceeds of stock on the open market. The award of a $1.1 million bonus to CEO, Bill Carter some feel is “egregious.” Whatever the case the markets have rewarded HEB with a slight gains. The stock has a steady RSI of 49.52 indicating lots of room for gains before the stock reaches either oversold or overbought territory.
Is HEB a solid investment at these levels? Get exclusive data and trends here.
Westinghouse Solar Inc. (OTCMKTS:WEST) has rallied from its drop in yesterday’s trading session and is now up 6.67%. The stock opened trading at 0.30 and has a range of 0.30 and 0.320 on volume of 28.71K.
There have been no recent developments surrounding WEST so investors seemed buoyed by promising outlooks in the solar sector. EPS this year is tipped to rise 28.58% and analysts have set a target price of 1.50 for the stock. WEST is still down 32.20% on its 50-day simple moving average and down 16.88% on its 20-day simple moving average. RSI continues to linger in oversold territory and stands at 24.46. There are 21.17 million shares outstanding in WEST and institutions own 3.40% of the stock. Insiders own 1.21% but their share of the transactions are down 86.97%.
How Should Investors Trade WEST Now? Get exclusive insights and updates here.
WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.